Johnson n Johnson schizophrenia drug gets wider US approval

Johnson & Johnson said on Friday that U.S. health regulators have broadened the approval for its Invega antipsychotic drug as a long-term maintenance treatment for schizophrenia.

The drug, a longer-acting version of J&J’s Risperdal, was approved in December to treat acute, or short-term, schizophrenia.

READ MORE @ at Reuters